Cargando…

Autophagy: a new target for nonalcoholic fatty liver disease therapy

Nonalcoholic fatty liver disease (NAFLD) has gained importance in recent decades due to drastic changes in diet, especially in Western countries. NAFLD occurs as a spectrum from simple hepatic steatosis, steatohepatitis to cirrhosis, and even hepatocellular carcinoma. Although the molecular mechanis...

Descripción completa

Detalles Bibliográficos
Autores principales: Mao, Yuqing, Yu, Fujun, Wang, Jianbo, Guo, Chuanyong, Fan, Xiaoming
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2016
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4822806/
https://www.ncbi.nlm.nih.gov/pubmed/27099536
http://dx.doi.org/10.2147/HMER.S98120
_version_ 1782425811737903104
author Mao, Yuqing
Yu, Fujun
Wang, Jianbo
Guo, Chuanyong
Fan, Xiaoming
author_facet Mao, Yuqing
Yu, Fujun
Wang, Jianbo
Guo, Chuanyong
Fan, Xiaoming
author_sort Mao, Yuqing
collection PubMed
description Nonalcoholic fatty liver disease (NAFLD) has gained importance in recent decades due to drastic changes in diet, especially in Western countries. NAFLD occurs as a spectrum from simple hepatic steatosis, steatohepatitis to cirrhosis, and even hepatocellular carcinoma. Although the molecular mechanisms underlying the development of NAFLD have been intensively investigated, many issues remain to be resolved. Autophagy is a cell survival mechanism for disposing of excess or defective organelles, and has become a hot spot for research. Recent studies have revealed that autophagy is linked to the development of NAFLD and regulation of autophagy has therapeutic potential. Autophagy reduces intracellular lipid droplets by enclosing them and fusing with lysosomes for degradation. Furthermore, autophagy is involved in attenuating inflammation and liver injury. However, autophagy is regarded as a double-edged sword, as it may also affect adipogenesis and adipocyte differentiation. Moreover, it is unclear as to whether autophagy protects the body from injury or causes diseases and even death, and the association between autophagy and NAFLD remains controversial. This review is intended to discuss, comment, and outline the progress made in this field and establish the possible molecular mechanism involved.
format Online
Article
Text
id pubmed-4822806
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher Dove Medical Press
record_format MEDLINE/PubMed
spelling pubmed-48228062016-04-20 Autophagy: a new target for nonalcoholic fatty liver disease therapy Mao, Yuqing Yu, Fujun Wang, Jianbo Guo, Chuanyong Fan, Xiaoming Hepat Med Review Nonalcoholic fatty liver disease (NAFLD) has gained importance in recent decades due to drastic changes in diet, especially in Western countries. NAFLD occurs as a spectrum from simple hepatic steatosis, steatohepatitis to cirrhosis, and even hepatocellular carcinoma. Although the molecular mechanisms underlying the development of NAFLD have been intensively investigated, many issues remain to be resolved. Autophagy is a cell survival mechanism for disposing of excess or defective organelles, and has become a hot spot for research. Recent studies have revealed that autophagy is linked to the development of NAFLD and regulation of autophagy has therapeutic potential. Autophagy reduces intracellular lipid droplets by enclosing them and fusing with lysosomes for degradation. Furthermore, autophagy is involved in attenuating inflammation and liver injury. However, autophagy is regarded as a double-edged sword, as it may also affect adipogenesis and adipocyte differentiation. Moreover, it is unclear as to whether autophagy protects the body from injury or causes diseases and even death, and the association between autophagy and NAFLD remains controversial. This review is intended to discuss, comment, and outline the progress made in this field and establish the possible molecular mechanism involved. Dove Medical Press 2016-03-24 /pmc/articles/PMC4822806/ /pubmed/27099536 http://dx.doi.org/10.2147/HMER.S98120 Text en © 2016 Mao et al. This work is published and licensed by Dove Medical Press Limited The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed.
spellingShingle Review
Mao, Yuqing
Yu, Fujun
Wang, Jianbo
Guo, Chuanyong
Fan, Xiaoming
Autophagy: a new target for nonalcoholic fatty liver disease therapy
title Autophagy: a new target for nonalcoholic fatty liver disease therapy
title_full Autophagy: a new target for nonalcoholic fatty liver disease therapy
title_fullStr Autophagy: a new target for nonalcoholic fatty liver disease therapy
title_full_unstemmed Autophagy: a new target for nonalcoholic fatty liver disease therapy
title_short Autophagy: a new target for nonalcoholic fatty liver disease therapy
title_sort autophagy: a new target for nonalcoholic fatty liver disease therapy
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4822806/
https://www.ncbi.nlm.nih.gov/pubmed/27099536
http://dx.doi.org/10.2147/HMER.S98120
work_keys_str_mv AT maoyuqing autophagyanewtargetfornonalcoholicfattyliverdiseasetherapy
AT yufujun autophagyanewtargetfornonalcoholicfattyliverdiseasetherapy
AT wangjianbo autophagyanewtargetfornonalcoholicfattyliverdiseasetherapy
AT guochuanyong autophagyanewtargetfornonalcoholicfattyliverdiseasetherapy
AT fanxiaoming autophagyanewtargetfornonalcoholicfattyliverdiseasetherapy